



Dr Nikhil Suresh Ghadyalpatil

MBBS, MD (G.Med), DNB (G.Med), MNAMS, DM (Medical Oncology), European Certification In Medical Oncology (ECMO) MRCP (Med Onco SCE), PDCR 18+ Years Experience

Hospitals

Apollo Health City, Jubilee Hills ,

Doctor's Working
Weekdays
Mon - Sat

Doctor's Working
Hours
10:00 - 18:00



Call Now



Book Appointment

Overview

Dr. Nikhil Suresh Ghadyalpatil is the **Director of Medical Oncology** at Apollo Health City, Jubilee Hills, Hyderabad with 18 years of extensive experience in the field. He holds an MBBS, MD in General Medicine, DNB in General Medicine, and a DM in Medical Oncology from the prestigious Tata Memorial Hospital. Additionally, Dr. Ghadyalpatil is certified in European Medical Oncology (ECMO) and holds an MRCP in Medical Oncology SCE, underscoring his advanced expertise and commitment to ongoing professional development. Dr. Ghadyalpatil specializes in the management of various malignancies, with a particular focus on personalized treatment plans, chemotherapy, immunotherapy, and targeted therapies. Dr. Nikhil Suresh Ghadyalpatil is a top medical oncologist, with expertise in diagnosing and treating a broad spectrum of cancers, including Adrenal Cancer, Ampullary Cancer, Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, among others. Dr. Ghadyalpatil has played a pivotal role in driving forward innovative treatment protocols aimed at improving patient outcomes. His expertise encompasses cutting-edge advancements such as novel chemotherapy regimens, immunotherapy, targeted therapies, precision oncology, antibody-drug conjugate

therapy, and cancer genetics, among others. His dedication to patient-centered care is evident in his approach, ensuring that each patient receives comprehensive support tailored to their unique needs. He is actively involved in clinical research and has contributed to numerous academic discussions and medical conferences, sharing insights on innovative treatment modalities and advancements in oncology. Fluent in English, Hindi, Telugu, and Marathi, Dr. Ghadyalpatil effectively communicates with a diverse patient population, fostering a compassionate and understanding environment. His unwavering commitment to medical excellence and patient care makes him a trusted partner in the journey toward recovery for his patients.

Experience

- **Director - Medical Oncology Apollo Hospitals, Telangana Region.** Office and Clinic: **Apollo Cancer Center, Jubilee Hills Hyderabad.**
- Consultant Medical Oncologist Clinical Director, , Yashoda Hospital, Hyderabad (2010-till February 2025)
- Ad-Hoc Consultant, Tata Memorial Center (2009-2010)
- Research Fellow, Spandan Heart Institute & Research Center, Nagpur (2002)

Membership

- **MRCP** UK (Speciality Certificate Examination) 2020
- European Certification in Medical Oncology (**ECMO**) 2007, 2013
- Professional Diploma In Clinical Research (**PDCR**) **2010**
- Advanced Certification in Molecular Oncology (ACMO) 2024
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Indian Collaborative Oncology Network (ICON)
- Editor in Chief: SAJC (South Asian Journal of Cancer)

Awards

- Recipient of ICON Oration 2022, Indore
- ASCO-International Development and Education Award (IDEA), Karmanos Cancer Center, Wayne State University, Detroit, 2010

- Professional Diploma in Clinical Research, 2008
- Coveted Membership of National Academy of Medical Sciences (MNAMS), 2008
- European Certification in Medical Oncology (ECMO), Barcelona, Spain, 2007
- Gold Medal for Securing 1st Position in PG Examination from KEMH, Mumbai, India, 2006
- B Braun Foundation Scholarship (National Scholarship) for outstanding performance during PG, 2003.
- Nagpur University Medal and Prize for Topper in Physiology, 1997

Research and Publication

Research

- **Vineet Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sharma, Rajani Yedla, Datopotamab Deruxtecan Versus Chemotherapy:** Primary results from TROPION-Breast01 study in metastatic hormone receptor-positive, HER2-negative breast cancer (J Clin Oncol, 2024).
- **Purvish M. Parikh, Amish Vora, Rajan Yadav, Akhil Kapoor, et al.:** Consensus Guidelines for the Use of CDK4/6 Inhibitors in HR+ve, HER2-ve Early Breast Cancer (South Asian J Cancer, 2024).
- **Bivas Biswas, Nikhil S. Ghadyalpatil, et al.:** Real-world study of lorlatinib's safety and efficacy as a second-line treatment for ALK-rearranged advanced non-small cell lung cancer in India (Ecancer, 2024).
- **Anant Ramaswamy, Anand Kulkarni, et al.:** Survival of trial-like vs non-trial-like patients with immunotherapy in advanced hepatocellular carcinoma in India (JCO Global Oncol, 2024).
- **Purvish M. Parikh, Sujith Kumar Mullapally, et al.:** Cervical Cancer in SAARC Countries (South Asian J Cancer, 2023).
- **D. Doval, S. Gupta, P. Mohapatra, et al.:** Primary results from IMpassion131, phase III trial of atezolizumab in metastatic triple-negative breast cancer (Ann Oncol, 2021).
- **Purvish M. Parikh, Sachin Hingmire, Nikhil Ghadyalpatil:** Lessons from Indonesia, Israel, and Iceland for India's next COVID-19 wave (South Asian J Cancer, 2021).
- **Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, et al.:** Ramucirumab's impact on advanced gastric cancer in Indian patients (South Asian J Cancer, 2021).
- **Ghanshyam Biswas, Avinash Pandey, Nikhil Ghadyalpatil, et al.:** Role of Cresp® in chemotherapy-induced anemia in cancer patients (South Asian J Cancer, 2020).
- **Nikhil S. Ghadyalpatil, et al.:** First-line management of metastatic non-small cell lung cancer in India (South Asian J Cancer, 2019).
- **Purvish M. Parikh, P. Narayanan, et al.:** Conflict of interest disclosure and interpretation (Indian J Med Sci, 2019).
- **Bhavesh Parekh, Nikhil Ghadyalpatil, et al.:** Immunotherapy in esophageal cancer update (International Journal of Molecular & Immuno Oncology, 2019).
- **Nikhil S. Ghadyalpatil, et al.:** First-line management of metastatic non-small cell lung cancer in India (South Asian J Cancer, 2019).
- **Purvish M. Parikh, Bhavesh Parekh, et al.:** Oncology Gold Standard consensus on counseling for molecular testing and personalized cancer care (Int J Mol ImmunoOncol, 2017).
- **Lung Cancer Consortium Asia, ICON, ISMPO, MOS, and API:** Indian consensus on treatment for advanced non-small cell lung cancer (Indian J Cancer, 2017).
- **Vedang Murthy, Adnan Calcuttawala, et al.:** HPV in head and neck cancer in India: Current status and consensus recommendations (South Asian J Cancer, 2017).

- **U. Batra, PM Parikh, et al.:** Oncology Gold Standard™ recommendations for treatment of advanced renal cell carcinoma (South Asian J Cancer, 2016).
- **Patil V, Noronha V, Joshi A, et al.:** Survey on implementation of antiemetic prescription standards in Indian oncology (J Glob Oncol, 2016).
- **Ghadyalpatil NS, et al.:** Gastrointestinal cancers treatment perspective in India (South Asian J Cancer, 2016).
- **P. M. Parikh, A. A. Ranade, et al.:** Lung cancer in India: Current status and promising strategies (South Asian J Cancer, 2016).
- **Kumar P, Bajpai J, et al.:** Management of febrile neutropenia in malignancy using MASCC score (Indian J Cancer, 2014).
- **Ghadyalpatil NS, et al.:** Case study on primary ovarian lymphoma with autoimmune hemolytic anemia (IJMPO, 2011).
- **Kumar P, Medhekar A, Ghadyalpatil NS, et al.:** Effect of age on bacterial infections and antibiotic sensitivity in cancer patients (Indian J Cancer, 2010).
- **Prabhash K, Medhekar A, Ghadyalpatil N, et al.:** Blood stream infections in cancer patients (Indian J Cancer, 2010).
- **Mardikar HM, Deshpande NV, Ghadyalpatil NS, et al.:** Patent protection and the need for value-based patents (Lancet, 2003).

Abstracts

1. **Jayant Khandare et al.** (ASCO 2024)

- Title: Single live circulating tumor cells capture and their genomic profile reveal enriched mutations of PIK3CA and HRR pathway in breast cancer patients.
- Abstract #454490, ASCO 2024.

2. **HM Mardikar, NV Deshpande, Aziz Khan, Nikhil Ghadyalpatil**

- Title: Is Coronary Angioplasty Inflammatory?
- Published in Indian Heart Journal (Sept-Oct 2003, Abstract).

3. **Aziz Khan et al.** (Sept-Oct 2003, Indian Heart Journal)

- Title: A Comparative Study of Anti-Factor Xa Activity of Parnaparin Versus Enoxaparin in Patients Undergoing Elective Coronary Angiography.
- Published in Indian Heart Journal (Sept-Oct 2003, Abstract).

4. **H. Menon et al.** (2007 ASCO Annual Meeting)

- Title: Outcome of patients of CML in AP and BC with Imatinib: A retrospective analysis of patients from India.
- Published in *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings (Vol 25, No. 18S, June 20 Supplement), Abstract #17531.

5. **A. V. Bakshi et al.** (J Clin Oncol 2008)

- Title: Evaluation of efficacy and safety of neoadjuvant chemotherapy with weekly paclitaxel in patients with locally advanced and large operable breast cancer.
- Published in *Journal of Clinical Oncology* (26: 2008, May 20 suppl; abstr 11593).

6. **R. Bharath et al.** (2008 ASCO Annual Meeting)

- Title: Treatment outcomes in patients with extensive stage small cell lung cancer – Experience from a tertiary Indian cancer centre.
- Published in *Journal of Clinical Oncology*, 2008 ASCO Annual Meeting Proceedings (Vol 26, No 15S, May 20 Supplement).

7. **Kumar Prabhash et al.** (ONCOCON 2009, Chennai, India)
 - Title: Outcome of patients of AML after Haematopoietic Stem Cell Transplantation – A single institution in India.
 - Presented at ONCOCON 2009, Chennai, India.
 8. **K. Prabhash et al.** (J Clin Oncol 2009)
 - Title: Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects.
 - Published in *Journal of Clinical Oncology* (27:15s, 2009, suppl; abstr 7079).
- Posters**
- **Ghadyalpatil NS, Menon H, Bharath R, Aggarwal.J.P, Kumar.P, Prasad.N, Goyal L Jain.P, Pramesh.CS, Parikh PM. Induction Chemotherapy Followed By Sequential Radiotherapy Or Chemoradiotherapy In Limited Stage Small Cell Lung Cancer – Experience From A Single Tertiary Indian Cancer Centre.** ESMO Sweden, 2008.
 - **H, Raut.N, Ghadyalpatil. N, Prabhash.K, Parikh.P.M. Gefitinib as first line therapy in Indian population with advanced adenocarcinoma lung; A prospective study.** WCLC 2009 San Francisco.
 - **Kumar Prabhash, Nikhil Ghadyalpatil, P.M. Parikh,C.S.Pramesh, R. Mistry, Priyanka Kudale, Neeta Hule, Shrushti. Demographic profile of consecutive Lung cancer patients-Experience from of a Single centre.** Asia Pacific Lung Cancer Conference, Hyderabad, 2008.
 - **Ameya Medhekar, Kumar Prabhash, Rohini Kelkar, Sanjay Biswas, Nikhil Ghadyalpatil, Randeep Singh, Purna Kurkure. The effect of age on the bacteria isolated and the antibiotic sensitivity pattern in infections among cancer patients.** 11th International Symposium on Febrile Neutropenia, Spain, 2009.
 - **Ameya Medhekar, Kumar Prabhash, Rohini Kelkar, Sanjay Biswas, Nikhil Ghadyalpatil, Amol Akare, Bhausaheb, Purna Kurkure. Comparison of in vitro activities of ceftizidime, Piperacillintazobactam and cefoperazone –sulbactam and the implication on empirical therapy in patients with cancer.** 11th International Symposium on Febrile Neutropenia, Spain 2009.
 - **Ghadyalpatil N., Banavali S., Kurkure P.,Arora B.,Bansal S.,Amare P.,Gujral S.,Choughule A.,Soy L.,Singh R. Excellent efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India.** J Clin Oncol 27:15s, 2009 (suppl; abstr 10047).
 - **Bajpai, K. Prabhash, A. Medhekar, R. Nair, P. Kurkure, Ghadyalpatil, S. Gupta, V. Noronha, P. D. Kudale, S. Banavali. Performance of MASCC score and other factors for identifying low-risk febrileneutropenic cancer patients.** J. Clin Oncol 28, 2010 (suppl; abstr e19533).
 - **Ostwal, N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, M. Sengar, V. Noronha, S. Biswas, B. Bhosale, S. Banavali. Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.** J Clin Oncol 28:15s, 2010 (suppl; abstr 6593).
 - **Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, S. Banavali, V. Noronha, V. Wabale, R. Singh, G. Goyal, V. Ostwal; Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.** J Clin Oncol 28:15s, 2010 (suppl; abstr 6594).

Frequently Asked Questions

1. Where does Dr Nikhil Suresh Ghadyalpatil practice?

Dr. Nikhil Suresh Ghadyalpatil is currently practicing at Apollo Hospitals, Jubilee Hills, Hyderabad.

2. What types of cancer does Dr. Nikhil Suresh Ghadyalpatil specialize in treating?

Dr. Nikhil Suresh Ghadyalpatil specializes in the treatment of various oncological conditions, including Adrenal Cancer, Ampullary Cancer, Anal Cancer, and several other cancer-related diseases.